Thanks for finding us at EHA

Who We Are and What We Do

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Pfizer has a long and proud heritage of addressing evolving hematologic malignancies and infectious disease challenges that continue to improve the lives of patients around the globe.


​​​​​​​Thank for finding us at EHA

Who We Are and What We Do

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Pfizer has a long and proud heritage of addressing evolving hematologic malignancies and infectious disease challenges that continue to improve the lives of patients around the globe.

Highlights From Your Congress


 

Hear from the Experts on Invasive Mould Infections (IMI) in Haematology Patients

BCMA Bispecific Antibody MOA

Approved Medicines


BOSULIF®
​​​​bosutinib

BESPONSA® 
inotuzumab ozogamicin

DAURISMO™
glasdegib

MYLOTARG™
gemtuzumab ozogamicin

CRESEMBA® 
isavuconazole

Commitment To Hematology


Scheduled
​​​​​​​Events

Symposium: Choosing a best‑practice approach for the management of IMD in haematology patients

Time: June 10, 2021 at 8:30 – 10:00 CEST


Elranatamab Oral Presentation 

Abstract No: S192
Session Title: T cell re-directing therapies in relapsed/refractory multiple myeloma​​​​​​​
Session Date and Time: On Demand


Check Back Soon For Any Additional Upcoming Events

 
 

Opportunities To Connect


Connect with Pfizer
through our Contact Form

Connect with Pfizer

Please fill out the form below. A member from the team will respond accordingly.

By providing your email address, you agree to receive an email response from Pfizer to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.

All fields marked with an asterisk ( *) are required.

Thank you for
contacting Pfizer.

A team member will respond to your inquiry.

Video title

X
X

PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.

X

PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.